CN115838393B - 用于fapi合成的中间体及其制备方法和应用 - Google Patents

用于fapi合成的中间体及其制备方法和应用 Download PDF

Info

Publication number
CN115838393B
CN115838393B CN202310124318.XA CN202310124318A CN115838393B CN 115838393 B CN115838393 B CN 115838393B CN 202310124318 A CN202310124318 A CN 202310124318A CN 115838393 B CN115838393 B CN 115838393B
Authority
CN
China
Prior art keywords
compound
amino
reaction
acid
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310124318.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN115838393A (zh
Inventor
吴晓明
王相玉
何田
杨清宝
成琳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yantai Lannacheng Biotechnology Co Ltd
Original Assignee
Yantai Lannacheng Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yantai Lannacheng Biotechnology Co Ltd filed Critical Yantai Lannacheng Biotechnology Co Ltd
Priority to CN202310124318.XA priority Critical patent/CN115838393B/zh
Publication of CN115838393A publication Critical patent/CN115838393A/zh
Application granted granted Critical
Publication of CN115838393B publication Critical patent/CN115838393B/zh
Priority to US18/861,835 priority patent/US20250382329A1/en
Priority to JP2025522077A priority patent/JP7838187B2/ja
Priority to CA3255143A priority patent/CA3255143A1/en
Priority to PCT/CN2024/077215 priority patent/WO2024169973A1/zh
Priority to KR1020247043121A priority patent/KR20250022067A/ko
Priority to EP24756343.0A priority patent/EP4585607A4/en
Priority to TW113105190A priority patent/TWI871182B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202310124318.XA 2023-02-16 2023-02-16 用于fapi合成的中间体及其制备方法和应用 Active CN115838393B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN202310124318.XA CN115838393B (zh) 2023-02-16 2023-02-16 用于fapi合成的中间体及其制备方法和应用
TW113105190A TWI871182B (zh) 2023-02-16 2024-02-15 用於fapi合成的中間體及其製備方法和應用
EP24756343.0A EP4585607A4 (en) 2023-02-16 2024-02-15 INTERMEDIATE USED FOR FAPI SYNTHESIS, ITS PREPARATION PROCESS AND ITS USE
JP2025522077A JP7838187B2 (ja) 2023-02-16 2024-02-15 Ｆａｐｉを合成するための中間体およびその調製方法と使用
US18/861,835 US20250382329A1 (en) 2023-02-16 2024-02-15 Intermediate used for fapi synthesis, preparation method therefor and application thereof
CA3255143A CA3255143A1 (en) 2023-02-16 2024-02-15 Intermediate used for fapi synthesis, preparation method therefor and application thereof
PCT/CN2024/077215 WO2024169973A1 (zh) 2023-02-16 2024-02-15 用于fapi合成的中间体及其制备方法和应用
KR1020247043121A KR20250022067A (ko) 2023-02-16 2024-02-15 Fapi 합성을 위한 중간체 및 그 제조방법과 응용

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310124318.XA CN115838393B (zh) 2023-02-16 2023-02-16 用于fapi合成的中间体及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN115838393A CN115838393A (zh) 2023-03-24
CN115838393B true CN115838393B (zh) 2023-05-05

Family

ID=85579761

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310124318.XA Active CN115838393B (zh) 2023-02-16 2023-02-16 用于fapi合成的中间体及其制备方法和应用

Country Status (8)

Country Link
US (1) US20250382329A1 (https=)
EP (1) EP4585607A4 (https=)
JP (1) JP7838187B2 (https=)
KR (1) KR20250022067A (https=)
CN (1) CN115838393B (https=)
CA (1) CA3255143A1 (https=)
TW (1) TWI871182B (https=)
WO (1) WO2024169973A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115838393B (zh) * 2023-02-16 2023-05-05 烟台蓝纳成生物技术有限公司 用于fapi合成的中间体及其制备方法和应用
WO2025091141A1 (zh) * 2023-10-30 2025-05-08 烟台蓝纳成生物技术有限公司 用放射性标记的截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂治疗甲状腺癌的方法
CN118754875B (zh) * 2024-09-06 2024-12-13 烟台蓝纳成生物技术有限公司 一种fapi前体化合物的制备工艺及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696631B2 (en) * 2016-05-09 2020-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
EP3749663A1 (en) * 2018-02-06 2020-12-16 Universität Heidelberg Fap inhibitor
CN109485642A (zh) * 2018-11-21 2019-03-19 希施生物科技（上海）有限公司 一种制备伊文氏蓝衍生物的方法
EP4126053A4 (en) * 2020-03-24 2024-11-20 Trustees Of Tufts College IMAGING AGENTS AND RADIOPHARMACEUTICALS TARGETING FAP, AND USES THEREOF
CN113582975A (zh) * 2021-07-03 2021-11-02 上海蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
WO2022170732A1 (zh) * 2021-02-10 2022-08-18 上海蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CN114369084B (zh) * 2021-02-10 2023-02-03 烟台蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CN113004371A (zh) * 2021-03-01 2021-06-22 上海蓝纳成生物技术有限公司 一种长循环半衰期的前列腺特异性膜抗原靶向化合物及其制备方法和应用
CN113603678A (zh) * 2021-08-10 2021-11-05 上海蓝纳成生物技术有限公司 一种靶向成纤维细胞活化蛋白的诊断药物及其制备方法
CN113621021A (zh) * 2021-08-10 2021-11-09 上海蓝纳成生物技术有限公司 一种靶向成纤维细胞活化蛋白的治疗药物及其制备方法
CN115677829A (zh) * 2022-10-19 2023-02-03 广州华复生物科技有限公司 一种糖基化靶向fap化合物、靶向fap标记配合物及其制备方法与应用
CN115838393B (zh) * 2023-02-16 2023-05-05 烟台蓝纳成生物技术有限公司 用于fapi合成的中间体及其制备方法和应用

Also Published As

Publication number Publication date
WO2024169973A1 (zh) 2024-08-22
TW202434565A (zh) 2024-09-01
EP4585607A4 (en) 2026-03-25
CA3255143A1 (en) 2025-03-28
US20250382329A1 (en) 2025-12-18
JP7838187B2 (ja) 2026-03-31
EP4585607A1 (en) 2025-07-16
JP2025534068A (ja) 2025-10-09
TWI871182B (zh) 2025-01-21
CN115838393A (zh) 2023-03-24
KR20250022067A (ko) 2025-02-14

Similar Documents

Publication Publication Date Title
CN115838393B (zh) 用于fapi合成的中间体及其制备方法和应用
JP4855924B2 (ja) 生物活性ベクターの放射性フッ素化法
CN115286697A (zh) 一种双重靶向化合物及其制备方法和应用
JP7289799B2 (ja) オリゴペプチドリンカー中間体及びその製造方法
CN118480031B (zh) 一种用于主动靶向表皮生长因子受体检测的近红外荧光探针及其制备方法与应用
CN108727468A (zh) 环肽、包含其的医药或化妆品组成物及其制备方法
JP5318874B2 (ja) 放射性フッ素化方法
CN104861161B (zh) 一种制备端氨基聚乙二醇的方法
CN107459526B (zh) 一种由戊高丝氨酸合成天然产物(±)-Pestaloxazine A的方法
WO2022099762A1 (zh) 一种抗体偶联物中间体及其制备方法
WO2020220020A1 (en) Silicon-fluoride heteroaromatic systems for applications in positron emission tomography (pet) molecular imaging
CN107459525B (zh) 一种由鸟氨酸合成天然产物(±)-Pestaloxazine A的方法
JP2888991B2 (ja) Ｎα−２−（４−ニトロフェニルスルフォニル）エトキシカルボニル−アミノ酸
RU2846888C2 (ru) Промежуточное соединение для синтеза fapi, способ его получения и применение
CN116568694B (zh) 碘酪氨酸衍生物及制备碘酪氨酸衍生物的方法
CN106083856A (zh) 一种可用于肿瘤治疗的嘌呤类丙氨酸衍生物及其制备方法和应用
WO2008075966A9 (en) Synthesis of a radiofluorinated peptide using photolabile protecting groups
RU2838403C1 (ru) СОЕДИНЕНИЕ ДВОЙНОГО НАЦЕЛИВАНИЯ ДЛЯ БЕЛКА АКТИВАЦИИ ФИБРОБЛАСТОВ (FAP) И ИНТЕГРИНА αvβ3, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ
CN101720328A (zh) 标记方法
TW202517662A (zh) 肽醇之固相簡便合成方法
WO2023103306A1 (zh) 一种氘代胞苷衍生物的制备方法
CN113234122A (zh) 一种用于抗体偶联药物的双臂中间体lnd1037的合成方法
WO2024260421A1 (zh) 一种类肽化合物及其配合物、药物组合物和应用
CN120309618A (zh) 吡咯并[2,1-f][1,2,4]三嗪-4(3H)-酮的合成方法
AU2024326972A1 (en) Linker-drug compounds and methods of making thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Room 101, Building 52, No. 500, Binhai East Road, Muping District, Yantai City, Shandong Province, 264199

Patentee after: Yantai Lannacheng Biotechnology Co.,Ltd.

Country or region after: China

Address before: Room 101, Building 52, No. 500, Binhai East Road, Muping District, Yantai City, Shandong Province, 264199

Patentee before: Yantai Lannacheng Biotechnology Co.,Ltd.

Country or region before: China

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 264117 Shandong Province Yantai City Muping District Dongxing Street No. 9 Building 21

Patentee after: Yantai Lannacheng Biotechnology Co.,Ltd.

Country or region after: China

Address before: Room 101, Building 52, No. 500, Binhai East Road, Muping District, Yantai City, Shandong Province, 264199

Patentee before: Yantai Lannacheng Biotechnology Co.,Ltd.

Country or region before: China